Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-QGlobeNewsWire • 08/23/24
Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development ProgramGlobeNewsWire • 07/31/24
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac DiseaseGlobeNewsWire • 06/27/24
Entero Therapeutics to Present Corporate Update at 2024 BIO International ConventionGlobeNewsWire • 05/22/24
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceGlobeNewsWire • 05/20/24